RENE GONZALEZ to Proto-Oncogene Proteins c-akt
This is a "connection" page, showing publications RENE GONZALEZ has written about Proto-Oncogene Proteins c-akt.
Connection Strength
0.316
-
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers. Cancer. 2024 May 15; 130(10):1784-1796.
Score: 0.180
-
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol. 2020 04; 85(4):673-683.
Score: 0.137